z-logo
open-access-imgOpen Access
In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study
Author(s) -
Andrew Walkty,
James A. Karlowsky,
Melanie Baxter,
Heather J. Adam,
George G. Zhanel
Publication year - 2018
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02068-18
Subject(s) - microbiology and biotechnology , morganella morganii , broth microdilution , proteus mirabilis , proteus , gram , providencia , aminoglycoside , antimicrobial , staphylococcus aureus , medicine , enterobacteriaceae , biology , antibiotics , escherichia coli , minimum inhibitory concentration , bacteria , biochemistry , genetics , gene
The Clinical and Laboratory Standards Institute (CLSI) broth microdilution method was used to evaluate thein vitro activities of plazomicin and comparator antimicrobial agents against 7,712 Gram-negative and 4,481 Gram-positive bacterial pathogens obtained from 2013 to 2017 from patients in Canadian hospitals as part of the CANWARD Surveillance Study. Plazomicin demonstrated potentin vitro activity againstEnterobacteriaceae (MIC90 ≤ 1 µg/ml for all species tested exceptProteus mirabilis andMorganella morganii ), including aminoglycoside-nonsusceptible, extended-spectrum β-lactamase (ESBL)-positive, and multidrug-resistant (MDR) isolates.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom